Supernus Pharmaceuticals, Inc. (Supernus) operates as a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
The company's diverse neuroscience portfolio includes ap…
Analysis
Middle-of-the-road
Supernus Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is expensive. You pay 39.2× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 15% yearly growth; analysts expect 28%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 10/20 on our value-creation score: creating some value.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202396
51
2023202420252026
All-time high
96
Jan 2023
All-time low
18
Jul 2023
Average rank
47
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
69
32
37
64
Price/Earnings
28
40
50
71
Price/Book
56
39
44
1
Dividend Yield
1
1
1
1
Value (overall)
45
41
29
16
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.